Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2019. Refer to TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | lenalidomide (Revlimid®) | ||
| Formulation | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg capsule | ||
| Reference number | 2614 | ||
| Indication | Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant |
||
| Company | Celgene Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 2116 | ||
| NMG meeting date | 08/06/2016 | ||
| AWMSG meeting date | 13/07/2016 | ||
| Ratification by Welsh Government | 26/07/2016 | ||
| Date of issue | 27/07/2016 | ||
| NICE guidance | TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
||
| Commercial arrangement | PAS | ||